ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Daiichi Sankyo, CSL and Sichuan Huiyu Pharmaceutical side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Daiichi Sankyo×CSL×Sichuan Huiyu Pharmaceutical×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Daiichi SankyoCSLSichuan Huiyu Pharmaceutical
studies on the registry49926816
open to participants now37189
phase 3 studies under way2160
reach primary completion within a year1144
programswith a study of their own in two years201011

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseDaiichi SankyoCSLSichuan Huiyu Pharmaceutical
Phase 1

Daiichi Sankyo: 7 of its 20 programs at phase 1

  1. DS1025Aphase 1
  2. DS3610Aphase 1
  3. DS5361Bphase 1
  4. DS9051Bphase 1
  5. valemetostatphase 1

and 2 more — sign in to see them all

35%
00%64%
Phase 225%

CSL: 2 of its 10 programs at phase 2

  1. VIT-2763phase 2
  2. anumigilimabphase 2
20%

Sichuan Huiyu Pharmaceutical: 4 of its 11 programs at phase 2

  1. Test Product HY07121phase 2
  2. HY05350phase 2
  3. Test product HY0001a for injectionphase 2
  4. Test Product HYP-6589phase 2
36%
Phase 3

Daiichi Sankyo: 4 of its 20 programs at phase 3

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. raludotatug deruxtecanphase 3
20%

CSL: 4 of its 10 programs at phase 3

  1. CSL300phase 3
  2. Immunoglobulins, Intravenousphase 3
  3. Four-factor Prothrombin Complex Concentratephase 3
  4. lonoctocog alfaphase 3
40%
00%
Approved, new studies

Daiichi Sankyo: 4 of its 20 programs at approved, new studies

  1. quizartinibapproved, new study
  2. bempedoic acidapproved, new study
  3. Ezetimibeapproved, new study
  4. Atorvastatinapproved, new study
20%

CSL: 4 of its 10 programs at approved, new studies

  1. Immunoglobulinsapproved, new study
  2. Hizentraapproved, new study
  3. alpha 1-Antitrypsinapproved, new study
  4. garadacimabapproved, new study
40%
00%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Daiichi Sankyo3 readouts · 1 phase 3·

Daiichi Sankyo, Dec ’26: 1 program whose next study reaches primary completion

  1. raludotatug deruxtecanphase 3 · Dec 30 · NCT04707248
····

Daiichi Sankyo, May ’27: 1 program whose next study reaches primary completion

  1. quizartinibapproved, new study · May 1 · NCT03793478
····

Daiichi Sankyo, Oct ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. trastuzumab deruxtecanphase 3 · Oct 1 · NCT05950945
CSL2 readouts · 1 phase 3·····

CSL, Apr ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. Four-factor Prothrombin Complex Concentratephase 3 · Apr 6 · NCT07094087
···

CSL, Aug ’27: 1 program whose next study reaches primary completion

  1. CSL300phase 3 · Aug 30 · NCT07619820
··
Sichuan Huiyu Pharmaceutical2 readouts · 0 phase 3······

Sichuan Huiyu Pharmaceutical, May ’27: 1 program whose next study reaches primary completion

  1. Test Product HY07121phase 2 · May 26 · NCT06639256

Sichuan Huiyu Pharmaceutical, Jun ’27: 1 program whose next study reaches primary completion

  1. Test product HY0001a for injectionphase 2 · Jun 0 · NCT07069062
····
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Daiichi Sankyo

New programs 1

  • olomorasibphase 2 · first study · Oct 16 · Carcinoma, Non-Small-Cell Lung

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 3

CSL

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 2

Sichuan Huiyu Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 1

Where they overlap

Conditions where at least two of them have programs: 2 in all. A program counts in each condition its studies name most.

ConditionDaiichi SankyoCSLSichuan Huiyu Pharmaceutical
Breast Neoplasms2 of 3 · compare here

Daiichi Sankyo in Breast Neoplasms: 3 programs

  1. trastuzumab deruxtecanphase 3
  2. datopotamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Daiichi Sankyo’s studies of Breast Neoplasms in search

–
Hematologic Neoplasms2 of 3 · compare here

Daiichi Sankyo in Hematologic Neoplasms: 2 programs

  1. Anti-CD37/DXd Antibody-drug Conjugate DS3790phase 2
  2. Combination drugphase 2

Their studies: Daiichi Sankyo’s studies of Hematologic Neoplasms in search

CSL in Hematologic Neoplasms: 1 program

  1. Hizentraapproved, new study

Their studies: CSL’s studies of Hematologic Neoplasms in search

–

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Daiichi Sankyo 14 of 20 · CSL 3 of 10 · Sichuan Huiyu Pharmaceutical 1 of 11 programs (14 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.